NO20035821L - Nye forbindelser som er kraftige inhibitoer av Na<O>+</O>/Ca<O>+</O> utvekslingsmekanismer og som nyttige i behandlingen av arrytmier - Google Patents

Nye forbindelser som er kraftige inhibitoer av Na<O>+</O>/Ca<O>+</O> utvekslingsmekanismer og som nyttige i behandlingen av arrytmier

Info

Publication number
NO20035821L
NO20035821L NO20035821A NO20035821A NO20035821L NO 20035821 L NO20035821 L NO 20035821L NO 20035821 A NO20035821 A NO 20035821A NO 20035821 A NO20035821 A NO 20035821A NO 20035821 L NO20035821 L NO 20035821L
Authority
NO
Norway
Prior art keywords
acyl
rog
arrhythmias
useful
treatment
Prior art date
Application number
NO20035821A
Other languages
English (en)
Norwegian (no)
Inventor
Eija Tiainen
Pentti Nore
Tuula Koskelainen
Leena Otsomaa
Pekka Kotovuori
Jukka Tenhunen
Sirpa Rasku
Olli Tormakangas
Arto Karjalainen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of NO20035821L publication Critical patent/NO20035821L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/90Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
NO20035821A 2001-07-10 2003-12-23 Nye forbindelser som er kraftige inhibitoer av Na<O>+</O>/Ca<O>+</O> utvekslingsmekanismer og som nyttige i behandlingen av arrytmier NO20035821L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20011507A FI20011507A0 (fi) 2001-07-10 2001-07-10 Uusia yhdisteitä
PCT/FI2002/000621 WO2003006452A1 (en) 2001-07-10 2002-07-10 New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias

Publications (1)

Publication Number Publication Date
NO20035821L true NO20035821L (no) 2004-02-24

Family

ID=8561628

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035821A NO20035821L (no) 2001-07-10 2003-12-23 Nye forbindelser som er kraftige inhibitoer av Na<O>+</O>/Ca<O>+</O> utvekslingsmekanismer og som nyttige i behandlingen av arrytmier

Country Status (28)

Country Link
US (1) US7425568B2 (fi)
EP (1) EP1412343B1 (fi)
JP (1) JP4113839B2 (fi)
KR (1) KR20040025697A (fi)
CN (1) CN1281597C (fi)
AR (1) AR036236A1 (fi)
AT (1) ATE338038T1 (fi)
AU (1) AU2002321339B2 (fi)
BR (1) BR0211070A (fi)
CA (1) CA2452918C (fi)
DE (1) DE60214388T2 (fi)
DK (1) DK1412343T3 (fi)
EA (1) EA006580B1 (fi)
ES (1) ES2269746T3 (fi)
FI (1) FI20011507A0 (fi)
HK (1) HK1068611A1 (fi)
HR (1) HRP20040133A2 (fi)
HU (1) HUP0400391A3 (fi)
IL (2) IL159647A0 (fi)
MX (1) MXPA04000267A (fi)
NO (1) NO20035821L (fi)
NZ (1) NZ530490A (fi)
PL (1) PL367958A1 (fi)
PT (1) PT1412343E (fi)
RS (1) RS50886B (fi)
UA (1) UA76168C2 (fi)
WO (1) WO2003006452A1 (fi)
ZA (1) ZA200400145B (fi)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20030030A0 (fi) * 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
CN101137639B (zh) 2005-03-11 2012-05-23 霍华德弗洛里生理医学实验研究所 类黄酮化合物及其用途
AU2011376746B2 (en) * 2011-09-12 2017-06-15 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
US8912224B2 (en) 2011-09-12 2014-12-16 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
JP5941637B2 (ja) * 2011-09-12 2016-06-29 サノフイ 置換2−(クロマン−6−イルオキシ)−チアゾール及び医薬としてのその使用
EP2567958B1 (en) * 2011-09-12 2014-10-29 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
CN102993195B (zh) * 2011-09-14 2017-05-17 赛诺菲 取代的2‑(色满‑6‑基氧基)噻唑及其作为药物的用途
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
TWI633095B (zh) * 2013-03-08 2018-08-21 賽諾菲公司 經取代-6-基氧基-環烷類及其作為醫藥品之用途
GB201416186D0 (en) 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
WO2019175464A1 (en) 2018-03-14 2019-09-19 Orion Corporation Compounds useful as inhibitors of sodium-calcium exchanger (ncx)
CA3187514A1 (en) 2020-07-28 2022-02-03 Andrew BELFIELD Fused bicyclic raf inhibitors and methods for use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2820817A (en) 1954-02-04 1958-01-21 Mcneilab Inc Oxygenated indan compounds and method of making the same
US3862232A (en) * 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
BE650081A (fi) 1963-07-03
GB1154119A (en) 1968-05-20 1969-06-04 Merck Ag E 3-Alkyl-Flavanones
FR2733685B1 (fr) * 1995-05-05 1997-05-30 Adir Utilisation des derives du benzopyrane pour l'obtention de compositions pharmaceutiques destinees au traitement des pathologies liees a l'echangeur c1-/hc03-, na+ independant
JPH0967336A (ja) 1995-09-04 1997-03-11 Kanebo Ltd 新規なイソチオウレア誘導体
EP0978506B1 (en) 1997-03-27 2003-01-08 Taisho Pharmaceutical Co., Ltd 2-phenoxyaniline derivatives
JPH1149752A (ja) 1997-08-05 1999-02-23 Taisho Pharmaceut Co Ltd フェノキシピリジン誘導体
DE19742508A1 (de) * 1997-09-26 1999-04-01 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
ES2191341T3 (es) 1997-10-20 2003-09-01 Taisho Pharmaceutical Co Ltd Derivados de la 2-fenoxianilina.
JPH11302235A (ja) 1998-04-15 1999-11-02 Taisho Pharmaceut Co Ltd フェノキシアルキルアミン誘導体
AU4360200A (en) 1999-04-23 2000-11-10 Bristol-Myers Squibb Company Bicyclic acyl guanidine sodium/proton exchange inhibitors and method
SK3292002A3 (en) 1999-09-17 2003-04-01 Nissan Chemical Ind Ltd Benzopyran derivative
FI20030030A0 (fi) * 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä

Also Published As

Publication number Publication date
PL367958A1 (en) 2005-03-07
JP4113839B2 (ja) 2008-07-09
CA2452918C (en) 2010-02-16
ES2269746T3 (es) 2007-04-01
DE60214388D1 (de) 2006-10-12
FI20011507A0 (fi) 2001-07-10
CA2452918A1 (en) 2003-01-23
DE60214388T2 (de) 2007-09-13
JP2005504738A (ja) 2005-02-17
RS50886B (sr) 2010-08-31
WO2003006452A1 (en) 2003-01-23
ZA200400145B (en) 2005-04-08
RS604A (en) 2006-12-15
PT1412343E (pt) 2006-12-29
UA76168C2 (en) 2006-07-17
ATE338038T1 (de) 2006-09-15
CN1281597C (zh) 2006-10-25
HRP20040133A2 (en) 2004-08-31
US20040235905A1 (en) 2004-11-25
BR0211070A (pt) 2004-06-15
AU2002321339B2 (en) 2007-06-21
EA200400161A1 (ru) 2004-06-24
HK1068611A1 (en) 2005-04-29
EP1412343A1 (en) 2004-04-28
NZ530490A (en) 2005-12-23
AR036236A1 (es) 2004-08-25
US7425568B2 (en) 2008-09-16
HUP0400391A2 (hu) 2004-12-28
HUP0400391A3 (en) 2008-03-28
IL159647A0 (en) 2004-06-01
DK1412343T3 (da) 2007-01-02
KR20040025697A (ko) 2004-03-24
CN1525966A (zh) 2004-09-01
EP1412343B1 (en) 2006-08-30
EA006580B1 (ru) 2006-02-24
IL159647A (en) 2008-04-13
MXPA04000267A (es) 2004-07-23

Similar Documents

Publication Publication Date Title
NO20035821L (no) Nye forbindelser som er kraftige inhibitoer av Na&lt;O&gt;+&lt;/O&gt;/Ca&lt;O&gt;+&lt;/O&gt; utvekslingsmekanismer og som nyttige i behandlingen av arrytmier
DK1263722T3 (da) Farmaceutiske sammensætninger, som indeholder azetidinderivat, nye azetidinderivater og fremstilling deraf
NO2011026I1 (no) Eribulin og farmasøytisk akseptable salter derav
NO20092033L (no) Nye forbindelser
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
NO20045235L (no) Tetrahydropyranylsyklopentyltetrahydropyridopyridinmodulatorer med kjemokinreseptoraktivitet
NO20051892L (no) Ny forbindelse
NO20064365L (no) Terapeutisk forbindelse
NO20051893L (no) Ny forbindelse
NO20035210L (no) 2-anilino-pyrimidinderivater som cyklinavhengige kinaseinhibitorer
NO20062713L (no) 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister
NO20044501L (no) [1,4] diazenino [6,7,1-IJ] kinolin-derivater som antipsykotis og antifedme-midler
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
NO20062905L (no) Nye hydroksaminsyreestere og farmasoytisk anvendelse derav
NO20054852L (no) GFAT inhibitorer
NO20073465L (no) Benzotiazol-derivater
NO20066055L (no) Pyridinderivater
NO20054669L (no) Substituerte kinobenzoxazinanaloger
DK0749424T3 (da) Naphthalenderivater som prostaglandin-I2-agonister
NO20062491L (no) Benzoksazinderivter og deres anvendelse
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20034311L (no) CCR5-antagonister for behandling av AIDS
NO20051089L (no) Bredspektrede 2-amino-benzotiazol-sulfonamid-HIV-proteaseinhibitorer
NO20040881L (no) Orale antidiabetes midler.
ATE330601T1 (de) Sulfonamide als matrix-metalloproteinase inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application